13 completed, 4 recruiting, 4 terminated, 3 not yet recruiting. 30 Phase 1, 10 Phase 2.
Follow Acidosis: new trials by email Literature Review of Acidosis trials Research Report on Acidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes PAL-119, Placebo - Healthy Volunteers and Diabetes Participants | Phase 1 / Phase 2 | Not yet recruiting | Paulex Bio Inc. | 147 | 2026-11-01 | 2026-10-28 |
| Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes Arginine hydrochloride, Sodium Chloride 0.9% - Diabetes (DM), Diabetic Ketoacidosis | Phase 1 / Phase 2 | Recruiting | David K Carroll | 60 | 2025-12-19 | 2026-02-12 |
| Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP) KETONE-IQ 20 grams (g), KETONE-IQ 40 grams (g) - Healthy Participants, Sleep | Phase 1 | Completed | Johns Hopkins University | 20 | 2025-12-18 | 2026-09-28 |
| Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism d-beta-hydroxybutrate, Placebo - Cognition, BDNF | Phase 1 | Not yet recruiting | University of Southern California | 50 | 2025-11-01 | 2025-10-20 |
| Adding Urea to the Final Dialysis Fluid Urea in the dialysate - Dysequilibrium Syndrome, ESRD | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 20 | 2025-09-16 | 2026-02-12 |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| Impact of Exogenous Ketones on Sleep Disruption in Vulnerable Populations Ketone-IQ (1,3 Butanediol) - Obstructive Sleep Apnea, Sleep | Phase 1 | Suspended | Johns Hopkins University | 30 | 2025-01-29 | 2026-06-23 |
| the Effect of Interdialytic Serum Bicarbonate Correction on Vascular Calcification in Hemodialysis Patients Oral sodium bicarbonate - End Stage Renal Disease (ESRD), Metabolic Acidosis | Phase 1 | Completed | Ain Shams University | 40 | 2023-09-01 | 2026-08-14 |
| Ketone Pharmacokinetic Study in HFrEF DeltaG (250 mg/kg), DeltaG (500 mg/kg) - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Duke University | 20 | 2023-06-02 | 2024-12-27 |
| Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers SGLT2 inhibitor, Controlled, Adaptive Study Diet - Ketones, Metabolism | Phase 1 | Active not recruiting | AdventHealth Translational Research Institute | 9 | 2023-03-16 | 2026-03-30 |
| Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) Dapagliflozin, Placebo oral tablet, Stress - Type 1 Diabetes, Diabetic Ketoacidosis | Phase 1 | Terminated | Kinderkrankenhaus auf der Bult | 2 | 2022-05-18 | 2024-12-09 |
| A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study mRNA-3927 - Propionic Acidemia | Phase 1 / Phase 2 | Recruiting | ModernaTX, Inc. | 50 | 2021-11-09 | 2026-03-23 |
| Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia mRNA-3927 - Propionic Acidemia | Phase 1 / Phase 2 | Recruiting | ModernaTX, Inc. | 77 | 2021-04-15 | 2026-01-22 |
| Nutritional Ketosis in Heart Failure beta hydroxybutyrate (BHB) ester, Placebo - Chronic Heart Failure | Phase 1 | Unknown | Thomas Jefferson University | 16 | 2020-06-01 | 2020-05-01 |
| Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production empagliflozin (Jardiance) 25 mg - Empaglifozin, Physiological Effects of Drugs | Phase 1 | Completed | National Institute on Aging (NIA) | 21 | 2019-03-28 | 2022-08-02 |
| Effects of Ketone Bodies on Cognition in Type 2 Diabetes Ketone infusion, Saline infusion - Type2 Diabetes, Ketonemia | Phase 1 | Completed | Bispebjerg Hospital | 18 | 2018-09-17 | 2019-02-20 |
| Exogenous Ketones and Glucose Tolerance Ketone monoester, Placebo - Ketones, Dietary Supplements | Phase 1 | Completed | University of British Columbia | 15 | 2018-03-26 | 2019-04-18 |
| Thiamine Supplementation in Patients With Septic Shock Thiamine, Placebos - Septic Shock, Shock, Septic | Phase 1 | Withdrawn | The Cleveland Clinic | 2016-11-05 | 2019-03-15 | |
| Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis Placebo, TRC101 - Acidosis | Phase 1 / Phase 2 | Completed | Tricida, Inc. | 135 | 2016-03-01 | 2020-01-14 |
Showing 20 of 30. Sign in to see all of them.
Ketosis (17) · Diabetes Mellitus, Type 1 (3) · Diabetic Ketoacidosis (3) · Acid-Base Imbalance (2) · Acidosis, Lactic (2) · Alzheimer Disease (2) · Amino Acid Metabolism, Inborn Errors (2) · Diabetes Mellitus (2) · Genetic Diseases, Inborn (2) · Hyperglycemia (2) · Insulin Resistance (2) · Kidney Failure, Chronic (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2)
Nutritional and Metabolic Diseases (30) · Acid-Base Imbalance (28) · Metabolic Diseases (28) · Nervous System Diseases (11) · Pathological Conditions, Signs and Symptoms (11) · Brain Diseases (9) · Central Nervous System Diseases (9) · Glucose Metabolism Disorders (6) · Pathologic Processes (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Signs and Symptoms (5)
Sodium Bicarbonate (2) · 1,3-butylene glycol (1) · 3-Hydroxybutyric Acid (1) · Arginine (1) · Biguanides (1) · Control Groups (1) · Diet (1) · Diet, Carbohydrate-Restricted (1) · Diet, Diabetic (1) · Diet, Sodium-Restricted (1) · Endothelium-Dependent Relaxing Factors (1) · Esters (1) · GSK2981710 (1) · Glucose (1) · Hypoglycemic Agents (1)
Johns Hopkins University (6) · ModernaTX, Inc. (2) · AdventHealth Translational Research Institute (1) · Ain Shams University (1) · Albert Einstein College of Medicine (1) · Bispebjerg Hospital (1) · Burke Rehabilitation Hospital (1) · David K Carroll (1) · Duke University (1) · George Washington University (1) · GlaxoSmithKline (1) · Kinderkrankenhaus auf der Bult (1) · Mallinckrodt (1) · National Institute on Aging (NIA) (1) · Paulex Bio Inc. (1)
United States (20) · Canada (3) · United Kingdom (3) · Denmark (2) · France (2) · Japan (2) · Netherlands (2) · Saudi Arabia (2) · Spain (2) · Bulgaria (1) · Egypt (1) · Georgia (1) · Germany (1) · Israel (1)
Jonathan Jun, MD (3) · Eric H Kossoff, MD (2) · Anne Chiaramello, Ph.D. (1) · Carolin I Dohle, MD (1) · Debra Regier, M.D., Ph.D. (1) · J. Eduardo Rame, M.D. (1) · Jane Little, MD (1) · Jens Rikardt Andersen, MD (1) · Jinesh Mehta, MD (1) · Josephine M Egan, M.D. (1) · Matthew K Abramowitz, MD, MS (1) · Melissa Erickson, PhD (1) · Ramin Sam, MD (1)
PMID 19183804, PMID 29102959, PMID 31599919, PMID 36577040, PMID 40139871
2015 (1), K23HL161348 (1), UH3TR003897 (1)